TrialLung cancer (Amsterdam, Netherlands)2010

VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.

David P Carbone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.